Ananke Therapeutics

Ananke Therapeutics is a biotechnology company pioneering the development of small molecule therapeutics that target the epitranscriptome. The company focuses on modulating RNA-modifying enzymes, specifically Methyltransferase-like 3 (METTL3), which plays a pivotal role in the regulation of mRNA function and is implicated in various cancers. By inhibiting these enzymes, Ananke aims to disrupt the survival mechanisms of malignant cells, particularly in indications like acute myeloid leukemia. Founded by leaders in RNA biology, the company is leveraging its proprietary platform to advance a pipeline of precision medicines for oncology and other high-need therapeutic areas. The firm was incubated by Polaris Partners and represents a significant effort to translate epitranscriptomic research into clinical applications.